The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams.

ESTEIN SM, FIORENTINO MA, PAOLICCHI FA, CLAUSSE M, MANAZZA J, CASSATARO J, GIAMBARTOLOMEI GH, CORIA LM, ZYLBERMAN V, FOSSATI CA, KJEKEN R, GOLDBAUM FA.

VACCINE

ELSEVIER SCI LTD

Año: 2009 vol. 27 p. 6704 - 6711

0264-410X

We have engineered the polymeric vaccine BLSOmp31 by decorating the highly immunogenic and decameric Brucella lumazine synthase with an exposed loop of the Brucella outer membrane protein Omp31. In the present study, we have immunized different groups of rams with the recombinant chimera rBLSOmp31 in two different adjuvants (Incomplete Freund Adjuvant-IFA and QUIL A) and with the plasmid pCIBLSOmp31 administered either by i.m. injection alone or by using electroporation. In addition, we have used a heterologous prime-boost strategy consisting of repeated pCIBLSOmp31 electroporation priming followed by a single protein boost. Both, chimera rBLSOmp31 in IFA and the prime-boost strategy induced the highest IgG specific antibodies with bacteriolytic activity. While electroporation-enhanced humoral immune responses as compared to pCIBLSOmp31 injection alone, the highest levels of specific IFN-gamma and protection against bacterial challenge were achieved with prime-boost (76%) and chimera rBLSOmp31 in IFA (63%). Taken together these results strongly support the usefulness of the chimera BLSOmp31 as a vaccine against Brucella ovis in ovine brucellosis.